Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 8Recurrence 3Neurofibrosarcoma 2Lymphoma, Large B-Cell, Diffuse 2Wilms Tumor 1Vascular Neoplasms 1Solitary Fibrous Tumors 1Smooth Muscle Tumor 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdoid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Nerve Sheath Neoplasms 1Neoplasms, Adipose Tissue 1Myoepithelioma 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Liposarcoma, Myxoid 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Histiocytoma, Angiomatoid Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1Granuloma, Plasma Cell 1Granular Cell Tumor 1

Interventions

Cyclophosphamide 8asciminib 7fludarabine phosphate 6fludarabine 5Mycophenolic Acid 5nilotinib 3Whole-Body Irradiation 3Thiotepa 3Tacrolimus 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Cyclosporine 3venetoclax 2Sirolimus 2Melphalan 2Filgrastim 2Dasatinib 2Cyclosporins 2treosulfan 1thymoglobulin 1selinexor 1ruxolitinib 1ponatinib 1plerixafor 1olverembatinib 1midostaurin 1merphos 1gilteritinib 1bosutinib 1blinatumomab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive × selinexor × 30 days × Clear all
NCT02091245 2026-05-29

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
16 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡